Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of Health-related Quality of Life for Hypothesized Medical States Associated with Cervical Cancer

  • Murasawa, Hideki (Department of Health Care Policy and Management, Graduate School of Comprehensive Human Sciences, University of Tsukuba) ;
  • Konno, Ryo (Dept. of Obstetrics and Gynecology, Jichi Medical University Saitama Medical Centre) ;
  • Okubo, Ichiro (Department of Health Care Policy and Management, Graduate School of Comprehensive Human Sciences, University of Tsukuba) ;
  • Arakawa, Ichiro (Faculty of Pharmaceutical Science, Teikyo Heisei University)
  • Published : 2014.12.18
Download PDF
⟨ Previous Next ⟩

Abstract

Background: When evaluating health-economics for cervical cancer prevention policies in Japan, it is important to use Japanese value settings. This study aimed to obtain preference-based measures (preference measures) for hypothesized health states among healthy Japanese women, and to examine differences between the EuroQol-5D (EQ-5D) and standard gamble (SG) instruments. Materials and Methods: The investigation was performed among female students at a nursing university. We used written hypothetical scenarios describing three grades of cervical intraepithelial neoplasia (CIN) and eight stages of cervical cancer, both at diagnosis and after medical intervention. Preference measures were evaluated using both EQ-5D and SG. Results: We received responses from 136 women. The mean number of respondents per stage was 24.6 (SD: 2.7). At diagnosis, average EQ-5D scores for CIN1, CIN2, CIN3, IA1, IA2, IB1, IB2, IIA, IIB, III, and IV stages were 0.84 (0.14), 0.78 (0.12), 0.73 (0.10), 0.78 (0.12), 0.72 (0.12), 0.63 (0.13), 0.64 (0.12), 0.68 (0.08), 0.62 (0.13), 0.55 (0.21), and 0.18 (0.24), respectively. Using one-way analysis of variance with the Tukey-Kramer method for multiple comparisons (each stage vs. CIN1), we found significant differences for IB1 and more advanced stages (p<0.05). After medical intervention, corresponding EQ-5D scores were 0.84 (0.12), 0.81 (0.12), 0.84 (0.12), 0.80 (0.15), 0.78 (0.11), 0.64 (0.15), 0.63 (0.15), 0.71 (0.15), 0.50 (0.17), 0.52 (0.17), 0.21 (0.28). The multiple comparisons identified significant differences for IB1 and more advanced stages, excepting IIA (p<0.05). SG evaluations were more variable and relatively higher than EQ-5D evaluations. Conclusions: We obtained preference measures for three grades of CIN1-3 and eight stages of cervical cancer. In combination with appropriate sensitivity analyses, these preference measures will provide a basis for an economic evaluation of cervical cancer prevention in Japan. We suggest that EQ-5D is appropriate for cost-utility analysis of this topic.

Keywords

References

  1. Cancer Statistics Japan Editorial Board. Cancer Statistics in Japan (2009). http://ganjoho.jp/professional/statistics/backnumber/2009_jp.html (11st February 2014).
  2. Canfell K, Chesson H, Kulasingam SL, et al (2012). Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine, 30, 157-67. https://doi.org/10.1016/j.vaccine.2012.06.091
  3. De Wit GA, Busschbach JJ, De Charro FT (2000). Sensitivity and perspective in the valuation of health status: whose values count? Health Econ, 9, 109-26. https://doi.org/10.1002/(SICI)1099-1050(200003)9:2<109::AID-HEC503>3.0.CO;2-L
  4. Drummond MF, O'Brien BJ, Stoddart GL, et al (1997). Methods for the Economic Evaluation of Health Care Programmes, Second Edition. Oxford University Press, Oxford, UK.
  5. Ferlay J, Soerjomataram I, Ervik M, et al (2012). GLOBOCAN 2012, Cancer Incidence and Mortality Worldwide, Version 1.0, IARC CancerBase No. 11. http://globocan.iarc.fr (10th December 2013).
  6. Galante J, Augustovski F, Colantonio L, et al (2011). Estimation and comparison of EQ-5D health states' utility weights for pneumococcal and human papillomavirus diseases in Argentina, Chile, and the United Kingdom. Value Health, 14, 60-4.
  7. Gold MR, Siegel JE, Russell LB, et al (1996). Cost-Effectiveness in Health and Medicine. Oxford University Press, Oxford, UK.
  8. Greenberg D, Fang C, Cohen JT, et al (2009). Preferences for Preferences. ISPOR 12th Annual European Congress, PMC56.
  9. Hashimoto H (1998). Economic evaluation of health: theories and underlying assumptions. Jpn J Health Econ Pol, 8, 53-65.
  10. Kobayashi M, Ohno T, Noguchi W, et al (2009). Psychological distress and quality of life in cervical cancer survivors after radiotherapy: do treatment modalities, disease after medical, and self-esteem influence outcomes? Int J Gynecol Cancer, 19, 1264-8. https://doi.org/10.1111/IGC.0b013e3181a3e124
  11. Korfage IJ, van Ballegooijen M, Wauben B, et al (2012). Having a Pap smear, quality of life before and after cervical screening: a questionnaire study. BJOG, 119, 936-44. https://doi.org/10.1111/j.1471-0528.2012.03344.x
  12. Konno R (2010). Efficient combination of primary and secondary prevention in cervical cancer. San Fujinkna no Zissai, 59, 553-8 (in Japanese).
  13. Konno R, Sasagawa T, Fukuda T, et al (2010). Cost-effectiveness analysis of prophylactic cervical cancer vaccination in Japanese women. Int J Gynecol Cancer, 20, 385-92. https://doi.org/10.1111/IGC.0b013e3181d189b8
  14. Lang HC, Chang K, Ying YH (2012). Quality of life, treatments, and patients' willingness to pay for a complete remission of cervical cancer in Taiwan. Health Econ, 21, 1217-33. https://doi.org/10.1002/hec.1786
  15. Matsuda A, Matsuda T, Shibata A, et al (2013). Cancer incidence and incidence rates in Japan in 2007: a study of 21 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jap J of Clinic Onc, 43, 328-36. https://doi.org/10.1093/jjco/hys233
  16. Ministry of Health, Labour and Welfare, Japan. Vital Statistics Japan (2012). http://ganjoho.jp/professional/statistics/statistics. html (26th November 2013).
  17. Ohara-Hirano Y, Kaku T, Hirakawa T, et al (2004). Uterine cervical cancer: a holistic approach to mental health and it's socio-psychological implications. Fukuoka Igaku Zasshi, 95, 183-94 (in Japanese).
  18. Singer S, Kuhnt S, Momenghalibaf A, et al (2010). Patients' acceptance and psychometric properties of the EORTC QLQCX24 after surgery. Gynecol Oncol, 116, 82-7. https://doi.org/10.1016/j.ygyno.2009.09.022
  19. Suzuki N, Ninomiya M, Maruta S, et al (2011). Psychological characteristics of Japanese gynecologic cancer patients after learning the diagnosis according to the hospital anxiety and depression scale. J Obstet Gynaecol Res, 37, 800-8. https://doi.org/10.1111/j.1447-0756.2010.01437.x
  20. Tamura M, Nozaki M, Fukuda T (1996). An empirical study on utility assessment methods for quality adjusted life years (QALYs). Jpn J Health Econ Pol, 3, 87-103.
  21. The Japanese EuroQol Translation Team (1998). The development of Japanese EuroQol instrument. J Health Care Soc, 8, 109-24 (in Japanese).
  22. Westra TA, Stirbu-Wagner I, Dorsman S, et al (2013). Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the costeffectiveness analysis of human papillomavirus vaccination in the Netherlands. BMC Infect Dis, 13, 75. https://doi.org/10.1186/1471-2334-13-75
  23. Yamamoto N, Mori R, Jacklin P, et al (2012). Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis. BJOG, 119, 177-86. https://doi.org/10.1111/j.1471-0528.2011.03036.x
  24. zur Hauzen H (1991). Human papillomaviruses in the pathogenesis of anogenital cancer. Virology, 184, 9-13. https://doi.org/10.1016/0042-6822(91)90816-T

Cited by

  1. Evaluation of Health-Related Quality of Life among Patients with Cervical Cancer in Indonesia vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3345
  2. Health-related quality of life as measured by the EQ-5D in the prevention, screening and management of cervical disease: A systematic review vol.26, pp.11, 2017, https://doi.org/10.1007/s11136-017-1628-z
  3. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer pp.1364-6893, 2019, https://doi.org/10.1080/01443615.2017.1416595